Stay updated on HER2 Therapy+Fulvestrant/Capecitabine in HR+/HER2+ MBC Clinical Trial
Sign up to get notified when there's something new on the HER2 Therapy+Fulvestrant/Capecitabine in HR+/HER2+ MBC Clinical Trial page.

Latest updates to the HER2 Therapy+Fulvestrant/Capecitabine in HR+/HER2+ MBC Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe study page for NCT04337658 now renders a 403 Forbidden error instead of displaying the study details, blocking access to the record; this is accompanied by a minimal header/footer indicating an access-denied page rather than the full study information.SummaryDifference21%

- Check36 days agoChange DetectedThe page now displays a new site revision label: Revision: v3.6.6, replacing the previous Revision: v3.6.5. This reflects an internal frontend update rather than a substantive content change.SummaryDifference0.1%

- Check57 days agoChange DetectedThe sponsor institution name is updated to Second Affiliated Hospital, Zhejiang University, School of Medicine to reflect the proper organizational naming. The page revision tag is updated to v3.6.5, changing the documented version of the study record.SummaryDifference0.3%

- Check71 days agoChange DetectedThe page's revision label was updated to v3.6.4, indicating a minor metadata update to the page.SummaryDifference0.0%

- Check93 days agoChange DetectedRevision tag on the study page was updated from v3.6.2 to v3.6.3. This indicates a small version update to the page metadata rather than a content change.SummaryDifference0.0%

- Check100 days agoChange DetectedThe page revision label was updated from v3.6.0 to v3.6.2, indicating a small update to the page rendering.SummaryDifference0.0%

Stay in the know with updates to HER2 Therapy+Fulvestrant/Capecitabine in HR+/HER2+ MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the HER2 Therapy+Fulvestrant/Capecitabine in HR+/HER2+ MBC Clinical Trial page.